secwatch.observer — SEC 8-K summary
======================================

Issuer:     Carisma Therapeutics Inc. (CARM)
CIK:        0001485003
Form:       8-K
Filed at:   2022-12-23T23:59:59+00:00
Accession:  0001485003-22-000167
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.02
LLM model:  deepseek-v4-flash:cloud@v2

Sesen Bio terminates license agreement with Qilu Pharma; pays $1.4M termination fee
--------------------------------------------------------------------------------

- Terminated exclusive license agreement with Qilu Pharmaceutical for Vicineum in Greater China.
- One-time aggregate payment of $1,400,000 to Qilu ($1.2M termination fee + $200K contingent).
- All rights to Vicineum in China, Hong Kong, Macau, and Taiwan revert to Sesen.
- Sesen retains global rights to Vicineum and is exploring strategic alternatives with a financial advisor.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1485003/000148500322000167/0001485003-22-000167-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1485003/000148500322000167/sesn-20221223.htm
  HTML page:      https://secwatch.observer/filing/0001485003-22-000167

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer